Topical, single dose bisphosphonate treatment reduced bone resorption in a rat model for prosthetic loosening.
Fluid pressure, instability or particles have been suggested to cause peri-prosthetic bone resorption. High intracapsular pressures have been reported in hip joints with loose prosthetic components, and oscillating fluid pressure has been shown to cause dramatic bone resorption in animal models. Resorption can be reduced by systemic bisphosphonate treatment in rat models with oscillating fluid pressure, but this has required higher doses than needed to inhibit normal remodelling. Bisphosphonates have high affinity to bone mineral. Topical application of the drug is therefore feasible. We used a previously described rat model where oscillating fluid pressure causes bone resorption. Before pressurization, a 1 mg/ml solution of alendronate was applied onto the bone surface for 1 min, after which excess bisphosphonate was rinsed away. Bone resorption was measured on histological slides as soft tissue area at the interface. Rats treated with topical alendronate had soft tissue areas reduced by half. Topical bisphosphonate treatment before cementing a joint implant could possibly reduce the risk of later loosening.
Astrand
Jörgen
J
Department of Orthopaedics, Lund University Hospital, S-22185 Lund, Sweden. jorgen.astrand@ort.lu.se
Aspenberg
Per
P
D000287:Administration, Topical; D019386:Alendronate / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D004195:Disease Models, Animal; D008297:Male; D009068:Movement; D010014:Osteolysis / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D011312:Pressure; D011475:Prosthesis Failure; D051381:Rats; D017207:Rats, Sprague-Dawley; D013977:Tibia / Q000187:drug effects* / Q000293:injuries / Q000473:pathology
D019386:Alendronate